HOTH News and Press, Hoth Therapeutics Inc. From 10/31/22

HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS PR Newswire MEETS PRIMARY AND SECONDARY ENDPOINTS SAFETY AND EFFICACY BIOLEXA led to significant improvement in disease severity as measured by SCOR...

Hoth Therapeutics ( NASDAQ: HOTH ) stock fell ~13% after the bell on Monday after the firm said it will effect a 1-for-25 reverse stock split effective as of Wednesday, Oct. 26. Once the reverse split becomes effective, Hoth Therapeutics ( HOTH ) will have ~1.3M sh...

Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022 PR Newswire NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, ann...

Hoth Therapeutics ( NASDAQ: HOTH ) said on Tuesday it had signed an agreement with Altasciences to develop and manufacture the HT-TBI drug product formulation for the treatment and/or prevention of secondary brain injury. HT-TBI will be developed as a ready-t...

Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke PR Newswire TBI is responsible for 2.8 million accidents and emergency department visits annually in the U.S. Global Acute Ischemic Stroke M...

Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders PR Newswire Treatment with HT-004 significantly reduced lung inflammation after ovalalbumin (OVA) challenge in an asthma and allergy m...

Presentation Times and Weblinks Released for Over 50 Presenting Companies Wednesday and Thursday, August 17-18, 2022 NEW YORK, NY / ACCESSWIRE / August 16, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day August Micro-Cap Confer...

Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference PR Newswire NEW YORK , Aug. 12, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced toda...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical, announced today proof-of-concept data recorded using cognitive and behavioral assessments in an Alzheimer’s disease mouse model (aged APP/PS1+/- mice), indicating that HT-ALZ has cognitive ther...

The nano-cap biopharma Hoth Therapeutics ( NASDAQ: HOTH ) jumped ~39% in the morning hours Tuesday after the company announced proof-of-concept data supporting its Alzheimer’s candidate HT-ALZ based on a mouse model. The chronic oral dosing of HT-ALZ over more t...